Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE 5 inhibition in mice

1Division of Cardiology, Department of Medicine, and 2Department of Comparative Medicine and Comparative Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 3Molecular Cardiology Research Institute, Tufts–New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA. 4Department of Pharmacology, University of North Carolina, Chapel Hill, North Carolina, USA.

[1]  D. Kass,et al.  Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. , 2009, Journal of the American College of Cardiology.

[2]  D. Kass,et al.  Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. , 2008, Cellular signalling.

[3]  S. Heximer,et al.  RGS4 Regulates Parasympathetic Signaling and Heart Rate Control in the Sinoatrial Node , 2008, Circulation Research.

[4]  K. Nakao,et al.  Regulator of G-Protein Signaling Subtype 4 Mediates Antihypertrophic Effect of Locally Secreted Natriuretic Peptides in the Heart , 2008, Circulation.

[5]  S. Oparil,et al.  Atrial Natriuretic Peptide Inhibits Transforming Growth Factor β–Induced Smad Signaling and Myofibroblast Transformation in Mouse Cardiac Fibroblasts , 2008, Circulation research.

[6]  W. Daniel,et al.  RGS protein specificity towards Gq- and Gi/o-mediated ERK 1/2 and Akt activation, in vitro. , 2007, Journal of biochemistry and molecular biology.

[7]  Xiaoguang Sun,et al.  Regulation of RGS2 and Second Messenger Signaling in Vascular Smooth Muscle Cells by cGMP-dependent Protein Kinase* , 2007, Journal of Biological Chemistry.

[8]  D. Kass,et al.  Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface , 2007, Nature Reviews Drug Discovery.

[9]  T. Wieland,et al.  Regulators of G protein signalling: a spotlight on emerging functions in the cardiovascular system. , 2007, Current opinion in pharmacology.

[10]  K. Murthy,et al.  Inhibition of Galphaq-dependent PLC-beta1 activity by PKG and PKA is mediated by phosphorylation of RGS4 and GRK2. , 2007, American journal of physiology. Cell physiology.

[11]  Franz Hofmann,et al.  cGMP-dependent Protein Kinase Type I Inhibits TAB1-p38 Mitogen-activated Protein Kinase Apoptosis Signaling in Cardiac Myocytes* , 2006, Journal of Biological Chemistry.

[12]  S. Dixon,et al.  Up-regulation of Endogenous RGS2 Mediates Cross-desensitization between Gs and Gq Signaling in Osteoblasts* , 2006, Journal of Biological Chemistry.

[13]  Xiang Li,et al.  RGS2 Determines Short-Term Synaptic Plasticity in Hippocampal Neurons by Regulating Gi/o- Mediated Inhibition of Presynaptic Ca2+ Channels , 2006, Neuron.

[14]  J. Molkentin,et al.  Regulation of cardiac hypertrophy by intracellular signalling pathways , 2006, Nature Reviews Molecular Cell Biology.

[15]  M. Greenwood,et al.  Regulatory mechanisms involved in modulating RGS function , 2006, Cellular and Molecular Life Sciences CMLS.

[16]  Wei Zhang,et al.  Regulation of cardiomyocyte signaling by RGS proteins: differential selectivity towards G proteins and susceptibility to regulation. , 2006, Journal of molecular and cellular cardiology.

[17]  Anthony J. Muslin,et al.  Akt1 Is Required for Physiological Cardiac Growth , 2006, Circulation.

[18]  P. Chidiac,et al.  RGS proteins have a signalling complex: interactions between RGS proteins and GPCRs, effectors, and auxiliary proteins. , 2006, Cellular signalling.

[19]  Wei Zhang,et al.  Selective Loss of Fine Tuning of Gq/11 Signaling by RGS2 Protein Exacerbates Cardiomyocyte Hypertrophy* , 2006, Journal of Biological Chemistry.

[20]  F. Hofmann,et al.  Function of cGMP-dependent protein kinases as revealed by gene deletion. , 2006, Physiological reviews.

[21]  Jens Jordan,et al.  Autonomic nervous system and blood pressure regulation in RGS2-deficient mice. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[22]  Guy Salama,et al.  Calmodulin kinase II inhibition protects against structural heart disease , 2005, Nature Medicine.

[23]  P. Insel,et al.  Multi-tasking RGS proteins in the heart: the next therapeutic target? , 2005, Circulation research.

[24]  G. Dorn,et al.  Protein kinase cascades in the regulation of cardiac hypertrophy. , 2005, The Journal of clinical investigation.

[25]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[26]  M. Zaccolo,et al.  cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism , 2004, Circulation research.

[27]  I. Cohen,et al.  A transgenic mouse model of heart failure using inducible Galpha q. , 2005, Journal of Biological Chemistry.

[28]  J. Sadoshima,et al.  Negative regulators of cardiac hypertrophy. , 2004, Cardiovascular research.

[29]  S. Kudoh,et al.  Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II , 2004, Nature Cell Biology.

[30]  Mark S Taylor,et al.  Inhibition of cGMP-dependent protein kinase by the cell-permeable peptide DT-2 reveals a novel mechanism of vasoregulation. , 2004, Molecular pharmacology.

[31]  Jian Xu,et al.  Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy , 2004, Circulation research.

[32]  R. Karas,et al.  Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure , 2003, Nature Medicine.

[33]  Jing Liu,et al.  Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. , 2003, The Journal of clinical investigation.

[34]  J. M. Wyss,et al.  Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. , 2003, The Journal of clinical investigation.

[35]  Luigi Fratta,et al.  Melusin, a muscle-specific integrin β1–interacting protein, is required to prevent cardiac failure in response to chronic pressure overload , 2003, Nature Medicine.

[36]  G. Boss,et al.  cGMP-dependent Protein Kinase Inhibits Serum-response Element-dependent Transcription by Inhibiting Rho Activation and Functions* , 2002, The Journal of Biological Chemistry.

[37]  T. Voyno-Yasenetskaya,et al.  Galpha(q) and Gbetagamma regulate PAR-1 signaling of thrombin-induced NF-kappaB activation and ICAM-1 transcription in endothelial cells. , 2002, Circulation research.

[38]  T. Wieland,et al.  Expression of ten RGS proteins in human myocardium: functional characterization of an upregulation of RGS4 in heart failure. , 2002, Cardiovascular research.

[39]  H. Drexler,et al.  Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Yacoub,et al.  Expression of RGS3, RGS4 and Gi alpha 2 in acutely failing donor hearts and end-stage heart failure. , 2001, European heart journal.

[41]  G. Dorn,et al.  RGS4 reduces contractile dysfunction and hypertrophic gene induction in Galpha q overexpressing mice. , 2001, Journal of molecular and cellular cardiology.

[42]  K. Chien,et al.  Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. , 2001, Nature medicine.

[43]  I. Whishaw,et al.  Regulation of T cell activation, anxiety, and male aggression by RGS2. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Molkentin,et al.  Calcineurin Promotes Protein Kinase C and c-Jun NH2-terminal Kinase Activation in the Heart , 2000, The Journal of Biological Chemistry.

[45]  G. Milligan,et al.  The regulator of G protein signaling RGS4 selectively enhances alpha 2A-adreoreceptor stimulation of the GTPase activity of Go1alpha and Gi2alpha. , 2000, The Journal of biological chemistry.

[46]  Anthony J. Muslin,et al.  RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. , 1999, The Journal of clinical investigation.

[47]  J. Ross,et al.  Loss of a gp130 Cardiac Muscle Cell Survival Pathway Is a Critical Event in the Onset of Heart Failure during Biomechanical Stress , 1999, Cell.

[48]  Anthony J. Muslin,et al.  RGS4 inhibits G-protein signaling in cardiomyocytes. , 1999, Circulation.

[49]  R. Lefkowitz,et al.  Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. , 1998, Science.

[50]  Jeffrey Robbins,et al.  A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.

[51]  J. Rottman,et al.  RGS3 and RGS4 are GTPase activating proteins in the heart. , 1998, Journal of molecular and cellular cardiology.

[52]  G. Dorn,et al.  Transgenic Galphaq overexpression induces cardiac contractile failure in mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[53]  S. Heximer,et al.  RGS2/G0S8 is a selective inhibitor of Gqalpha function. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[54]  J. Sadoshima,et al.  Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro , 1993, Cell.